Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

Nature Reviews Cardiology, Published online: 15 September 2021; doi:10.1038/s41569-021-00627-zIn a clinical first, empagliflozin treatment cuts the risk of cardiovascular death and hospitalization compared with placebo in patients with heart failure with preserved ejection fraction.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research